[et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”88f366a5-bf49-48d9-a338-ab22706b73e7″ global_colors_info=”{}”][et_pb_row _builder_version=”4.18.0″ _module_preset=”default” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||||false|false” custom_padding_tablet=”10px||||false|false” custom_padding_phone=”0px||||false|false” custom_padding_last_edited=”on|phone” global_colors_info=”{}”][dipi_breadcrumbs _builder_version=”4.16″ _module_preset=”default” max_width=”800px” global_colors_info=”{}”][\/dipi_breadcrumbs][et_pb_divider color=”#EEEEEE” _builder_version=”4.16″ _module_preset=”default” max_width=”800px” min_height=”1px” height=”20px” custom_margin=”||3px|||” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.18.0″ _module_preset=”8738c908-7375-4c6c-99a7-9f91f8a3c099″ header_font_size=”56px” width=”93.2%” max_width=”800px” custom_margin=”|23px|17px|||” custom_padding=”|37px||||” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_menu menu_id=”93″ active_link_color=”#21242A” _builder_version=”4.18.0″ _module_preset=”default” max_width=”800px” global_colors_info=”{}”][\/et_pb_menu][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”tps” _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ custom_padding=”30px||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
TPS\u00ae\u202fis\u202fa tumor activity marker assay used to support prognosis, treatment monitoring, and patient follow-up for various epithelial cancers, including breast, colorectal, ovarian, and prostate cancer.<\/p>\n
TPS\u00ae\u202fmeasures soluble fragments of cytokeratin 18, which is over-expressed in epithelial cells and particularly in many types of cancer. This information is crucial for early detection of cancer recurrence and the quick assessment of treatment efficacy.<\/p>\n
The tumor marker TPS\u00ae\u202fis a reliable indicator of tumor cell activity particularly useful in patient management for different carcinomas. Compared with conventional tumor mass markers, the activity marker TPS\u00ae provides the clinician with earlier signals about the course of the disease. TPS\u00ae is particularly useful in treatment monitoring and surveillance of patients with epithelial cell carcinomas e.g. breast, prostate, and ovarian cancer.<\/p>\n
The TPS\u00ae ELISA only for China is manufactured and distributed by IDL Biotech.<\/p>\n
<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_button button_url=”http:\/\/immunotech.cz\/tps” url_new_window=”on” button_text=”IRMA” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2021\/05\/tps.jpg” alt=”tps tumor activity marker” title_text=”tps” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
TPS\u00ae ELISA assay is a valuable tumor marker for epithelial cancer, generating clinical information in breast and prostate cancer but also valuable in other forms of epithelial cell tumors such as colorectal and ovarian cancer.<\/p>\n
[\/et_pb_text][et_pb_toggle title=”References for TPS\u00ae” disabled_on=”off|off|off” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
TPS\u00ae\u202fgeneral<\/strong> 2.\u202fRydlander L., et al. Molecular characterization of a tissue-polypeptide specific antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem. 1996; 241: 309-314<\/a><\/p>\n TPS\u00ae\u202fin breast<\/strong> TPS\u00ae\u202fin prostate <\/strong> TPS\u00ae\u202fin ovarian <\/strong> [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”monototal” _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n MonoTotal\u00ae\u202fis a quantitative immunoassay that specifically measures defined epitopes on cytokeratin 19, 8, and 18. The test result is directly proportional to the concentration of soluble cytokeratin fragments in serum. An elevated level of soluble cytokeratin fragments in patient samples is an indication of epithelial tumor cell activity.<\/p>\n Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer mortality worldwide. Patients may suffer from one of two cancer types: Non-Small Cell Lung Cancer (NSCLC), or the less common,\u202fSmall-Cell Lung Cancer (SCLC).<\/p>\n Cancer biomarkers\u202fare effective for prognostic evaluation and monitoring of disease.\u202fMonoTotal\u00ae\u202fis a sensitive and efficient tool for managing patients with Non-Small Cell Lung Cancer (NSCLC).<\/p>\n With\u202fMonoTotal\u00ae, physicians receive an early indication of disease status, measured in terms of tumor cell activity rather than more conventional tumor burden measurements.\u202fMonoTotal\u00ae provides the physician with a reliable monitoring aid for disease progression and treatment in lung cancer patients.<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_button button_url=”http:\/\/immunotech.cz\/monototal” url_new_window=”on” button_text=”IRMA” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/couple-running.jpeg” title_text=”Cheerful active senior couple jogging in the park. Exercise together to stop aging.” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n MonoTotal\u00ae\u202fcorrelates well with tumor cell activity and the extent of the disease. Studies published during the last years show that\u202fMonoTotal\u00aehas a strong association with clinical response in patients.\u202fMonoTotal\u00aedemonstrates high sensitivity in patients with NSCLC, independent of histotype. The overall sensitivity is about 70-75%, at 95% specificity, and correlates well with tumor cell activity and the extent of the disease.<\/p>\n [\/et_pb_text][et_pb_toggle title=”References for MonoTotal\u00ae” disabled_on=”off|off|off” _builder_version=”4.22.1″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n 1.\u202fBarak, V. et al. Clinical utility of cytokeratin as a tumor marker. Clin Biochem. 2004;37:529-540.<\/a><\/p>\n 2. Eriksson, P. et al. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment. Neoplasma. 2006;53:285-290.<\/a><\/p>\n 3. Topolcan, O. et al. The importance of MonoTotal\u00ae\u202ffor primary diagnosis of patients with non-small cell lung cancer (NSCLC). Anticancer Res. 2008;28:4038-4039.<\/a><\/p>\n 4. Kim, DW. et al. Evaluation of usefulness for MonoTotal\u2122 in non-small cell lung cancer. J Nucl Med Tech. 2009;13:171-174.<\/p>\n 5. Wojcik, E. et al. Evaluation of the diagnostic utility of MonoTotal\u00ae\u202fin lung cancer patients. J Lab Diagn. 2009; 45:75-80.<\/p>\n 6. Topolcan, O. et al. (Abstract). MonoTotal\u00ae\u202f\u2013 prognosis and therapy control in patients with non small cell lung cancer (NSCLC). XIIth International Symposium on Biology and Clinical Usefulness of Tumor Markers, February 4-7, 2009, Barcelona, Spain.<\/p>\n 7. Prazakova, M. et al. The role of MonoTotal\u00ae\u202fin the primary diagnosis, prognosis and follow-up of patients with non-small cell lung cancer (NSCLC) Anticancer Res. 2011;31:3107-3112.<\/a><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”ubc” _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n UBC\u00ae\u202fis an immunoassay for both primary diagnosis and monitoring of bladder cancer. The test specifically measures soluble fragments of cytokeratin 8 and 18 in urine samples. Elevated amounts of cytokeratin protein fragments are present in the urine of many individuals with bladder cancer, even at the early stages of the disease.<\/p>\n <\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_button button_url=”http:\/\/immunotech.cz\/ubc-elisa” url_new_window=”on” button_text=”ELISA” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”http:\/\/immunotech.cz\/UBC” url_new_window=”on” button_text=”IRMA” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2021\/05\/UBC-scaled.jpg” title_text=”UBC” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n UBC\u00ae assay is a valuable tumor marker for epithelial cancer, generating clinical information in bladder cancer.<\/p>\n [\/et_pb_text][et_pb_toggle title=”References” disabled_on=”off|off|off” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n 1. Mian, C., et al. Comparison of two qualitative assays, the UBC Rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urol 2000; 56: 228-231.<\/a><\/p>\n 2. Sil\u00e9n, \u00c5., et al. Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer. Oncol Rep 2000; 7: 1269-1274.<\/a><\/p>\n 3. Sumi, S., et al. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 2000; 296:111-120.<\/a><\/p>\n 4. S\u00e1nchez-Carbayo, M. et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, Cyfra 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001; 165:1462-1467.<\/a><\/p>\n 5. Giannopoulos, A. et al. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001; 166:470-475.<\/a><\/p>\n 6. Arai, K., et al. Clinical evaluation of urinary bladder cancer antigen (UBC) measurement for detection of transitionalcell carcinoma of the bladder: comparison to urinary NMP22 test, BTAstat test and voided urine cytology test. Jpn J Urol Surg 2009; 22: 567-574.<\/a><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”tpacyk” _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n TPAcyk\u2122 is an indicator of tumor cell activity and is useful in the management of patients with carcinomas of epithelial origin. This cytokeratin based tumor marker gives early and distinct measurements of ongoing tumor cell activity and serves as an efficient tool for the detection of changes in the disease state. TPAcyk\u2122 is a general indicator of tumor cell activity, particularly for monitoring of treatment and follow-up of different epithelial carcinoma. TPAcyk\u2122 measures key epitopes of Tissue Polypeptide Antigen (TPA) fragments. The antibodies used in the test are specific for cytokeratin 8 and 18 in serum. Being specific for a certain type of cells, TPAcyk\u2122 has proven useful for monitoring of epithelial cell cancer diseases. By establishing TPAcyk\u2122 in routine care, this marker can be beneficially used for monitoring more than one disease.]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_button button_url=”http:\/\/immunotech.cz\/UBC” url_new_window=”on” button_text=”IRMA” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/09\/TPAcyk.jpg” title_text=”TPAcyk” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” custom_padding=”||1px|||” global_colors_info=”{}”]<\/p>\n TPAcyk\u2122 assay is a valuable tumor marker for epithelial cancer, generating clinical information in different types of malignancies.<\/p>\n [\/et_pb_text][et_pb_toggle title=”References” disabled_on=”off|off|off” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n 1. Mian, C., et al. Comparison of two qualitative assays, the UBC Rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urol 2000; 56: 228-231.<\/a><\/p>\n 2. Sil\u00e9n, \u00c5., et al. Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer. Oncol Rep 2000; 7: 1269-1274.<\/a><\/p>\n 3. Sumi, S., et al. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 2000; 296:111-120.<\/a><\/p>\n 4. S\u00e1nchez-Carbayo, M. et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, Cyfra 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001; 165:1462-1467.<\/a><\/p>\n
1.\u202fBarak V., et al. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37:529-540<\/a><\/p>\n
3. \u202fAhn S.K., et al. Preoperative serum tissue polypeptide-specific antigen is a valuable prognostic marker in breast <\/a>cancer. Int J Cancer. 2013; 132:875-881\u00a0<\/a><\/p>\n
4. Kil P.J., et al. Tissue polypeptide specific (TPS) determination before and during intermittant maximal androgen blockade in patients with prostatic carcinoma. Euro Urol. 2003; 43:31-38<\/p>\n
5. Van Dalen A., et al. Significance of serum CA125 and TPS antigen levels for detemination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaec Oncol. 2009; 30:609-615<\/p>\nMonoTotal\u00ae<\/h6>\n
For high sensitivity in NSCLC<\/h3>\n
Find more information<\/h3>\n
Clinical evaluation<\/h3>\n
UBC\u00ae<\/h6>\n
UBC\u00ae\u202fELISA for Bladder Cancer detection<\/h3>\n
UBC\u00ae\u202fis available in ELISA and Rapid format.<\/h4>\n
Find more information\u00a0<\/h3>\n
Clinical evaluation<\/h3>\n
TPAcyk<\/b>\u2122<\/h6>\n
TPAcyk\u2122 for indication of tumor cell activity<\/h3>\n
Find more information<\/h3>\n
Clinical evaluation<\/h3>\n